The launch price of Sacituzumab govitecan in mainland China

Sacituzumab govitecan is a first-in-class Trop-2-directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including more than 90% of breast and bladder cancers. Gosatuzumab is intentionally designed with a proprietary hydrolyzable linker attached to the topoisomerase I inhibitor payload SN-38. This unique combination provides potent activity in Trop-2 expressing cells and microenvironments.

Gosatuzumab has been approved in more than 35 countries and is under multiple additional regulatory reviews globally for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of which is used to treat metastatic disease. In the United States, gosatuzumab is also approved under the accelerated approval pathway for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who have previously received platinum-containing chemotherapy and a programmed death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor.

Gosatuzumab The original drug has been launched in China, but it has not yet been included in the medical insurance. The price of a 100mg bottle may be around 10,000 yuan, which is relatively expensive. Gosatuzumab Original drug marketed overseas has three versions: European version, American version, and Singapore version. SpecificationsThe price of each 100 mg bottle may be around RMB 10,000-35,000 (the price may fluctuate due to exchange rates). The ingredients of gosatuzumab sold domestically and abroad are basically the same. There is currently no generic version of gosatuzumab available on the market. For specific prices and drug information, please consult your medical consultant.